Ensuring the Safety & Effectiveness of Treatment

The clinical trial market in India is a rapidly growing industry. It is estimated that the market will reach $5 billion mark by 2025, driven by rising investments from pharmaceutical and biotechnology companies. The country has a large pool of skilled professionals, a well-developed healthcare infrastructure, and an increasing number of regulatory approvals for drug trials. This has made India an attractive destination for foreign companies to conduct clinical trials. In addition, the government's initiatives to improve access to healthcare and reduce costs have also helped drive growth in the sector. With these factors in play, it is likely that the Indian clinical trial market will continue to grow at a rapid pace in the years ahead. Realizing its potential, we have put the spotlight on this segment in this special issue.

The cover story of the issue features Renown Clinical Services (RCS) which is a Nephrology group specializing in the management of patients with kidney diseases. Founded in 2015, it has grown from two nephrologists to a group of nephrologists, research coordinators, dialysis managers, dialysis technicians and nurses. RCS is a group of 20 doctors, and therefore has a large patient base. Its nephrologists are leading KOLs in their specializations. Its main aim is to bring together a network of doctors and hospitals from different parts of India to be part of the clinical trials conducted by RCS. Reading on, you will find more such stories.

In addition, the issue also acquaints you with the other top startups in this domain. After studying the industry landscape in-depth, Industry Outlook has zeroed in on the top 10 startups that have excelled in this field with their meticulous approach. Having proven their dedication in order to meet the customer expectations in an end-to-end manner, these companies have stood out from the crowd.

We look forward to receiving your feedback and suggestions.